Annovis Bio (NYSE: ANVS) was featured in an interview with Today’s Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University’s Institute for Population Health, joined host Jane King to discuss clinical trials of a new drug that is showing promise for the treatment of neurodegenerative diseases like Alzheimer’s (“AD”) and Parkinson’s (“PD”) and their impact on population health.
“We have over 7 million people with neurodegeneration in the United States, and it is a huge problem. We think of the patients, but we should also think of the caregivers, because the caregivers are very much affected by it too,” said Dr. Maccecchini, going on to explain that Annovis is seeking funding for the next phase trials of a drug in development that attacks the root causes of Alzheimer’s and Parkinson’s diseases and could help millions of patients.
“Most people have heard of plaque in Alzheimer’s and maybe Lewy bodies in Parkinson’s,” Dr. Maccecchini explained. “Our drug attacks plaque, tangles and Lewy bodies. It targets the toxic proteins that kill nerve cells in the brain, and it addresses more than one. If you have more than one toxic protein, just removing one still leaves others to kill nerve cells. Our drug actually protects nerve cells from dying.”
To view the full press release, visit https://ibn.fm/34ojl
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN